Table 2.
Incidence of adverse events.
| VPZ group (n = 72) | PPI group (n = 69) | P value VPZ versus PPI | RPZ group (n = 59) | P value VPZ versus RPZ | |
|---|---|---|---|---|---|
| Overall | 19 (26.3%) | 26 (37.7%) | 0.1505 | 20 (33.9%) | 0.3497 |
| Loose stool | 12 (16.6%) | 12 (17.4%) | 0.9089 | 9 (15.3%) | 0.8265 |
| Diarrhea | 6 (8.3%) | 10 (14.5%) | 0.2490 | 8 (13.6%) | 0.3354 |
| Dysgeusia | 3 (4.1%) | 6 (8.7%) | 0.3192 | 5 (8.5%) | 0.4664 |
| Skin eruption | 1 (1.4%) | 3 (4.3%) | 0.3591 | 2 (3.4%) | 0.5881 |
| Abdominal bloating | 1 (1.4%) | 2 (2.9%) | 0.6143 | 1 (1.7%) | 1.0000 |
| Epigastralgia | 0 (0%) | 2 (2.9%) | 0.2377 | 2 (3.4%) | 0.4504 |
| Constipation | 1 (1.4%) | 1 (1.4%) | 1.0000 | 1 (1.7%) | 1.0000 |
| Nausea | 1 (1.4%) | 1 (1.4%) | 1.0000 | 1 (1.7%) | 1.0000 |
| Others | 2 (2.8%) | 4 (5.8%) | 0.4348 | 3 (5.1%) | 0.6571 |
Data are expressed as number (percentage). Statistical analyses were conducted with the chi-square test or Fisher's exact test. VPZ group, treatment with vonoprazan, amoxicillin, and clarithromycin; PPI group, treatment with rabeprazole or lansoprazole, amoxicillin, and clarithromycin; RPZ group, treatment with rabeprazole, amoxicillin, and clarithromycin.